Tumor Necrosis Factor

Novel Mechanism of Action for Adalimumab Underlying its Anti-Inflammatory Properties

A drug commonly used to treat rheumatoid arthritis (RA), adalimumab (also known as Humira), has long been thought to exert its anti-inflammatory effects through specific binding to Tumor Necrosis Factor-α (TNF α), preventing it from interacting with TNF receptors. Patients with RA have elevated levels of TNF in their synovial fluid, which greatly contribute to…

Next post in Rheumatology